

107



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
 United States Patent and Trademark Office  
 Address: COMMISSIONER FOR PATENTS  
 P.O. Box 1450  
 Alexandria, Virginia 22313-1450  
 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/856,374	05/21/2001	Ryuichi Morishita	Q64360	8301
7590	10/28/2004		EXAMINER	
Sughrue Mion Zinn Macpeak & Seas 2100 Pennsylvania Avenue N W Washington, DC 20037-3213			LI, QIAN JANICE	
			ART UNIT	PAPER NUMBER
			1632	

DATE MAILED: 10/28/2004

Please find below and/or attached an Office communication concerning this application or proceeding.



UNITED STATES DEPARTMENT OF COMMERCE  
Patent and Trademark Office  
Address: COMMISSIONER OF PATENTS AND TRADEMARKS  
Washington, D.C. 20231

SERIAL NUMBER	FILING DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NO.
---------------	-------------	-----------------------	---------------------

09/856,374 5/21/01 Morishita et al 964360

EXAMINER
----------

G. Janice Li

ART UNIT	PAPER NUMBER
----------	--------------

1632 10/13/04

DATE MAILED:

### EXAMINER INTERVIEW SUMMARY RECORD

All participants (applicant, applicant's representative, PTO personnel):

(1) G. Janice Li, PTO (3) Susan J Mack, Appl. Rep.  
(2) Amy Nelson, PTO (4) Lisa Stahl "

Date of interview 10/13/04

Type: ☐ Telephonic ☒ Personal (copy is given to ☐ applicant ☐ applicant's representative).

Exhibit shown or demonstration conducted: ☒ Yes ☐ No. If yes, brief description: Yonemitsu et al

Agreement ☐ was reached with respect to some or all of the claims in question. ☐ was not reached.

Claims discussed: 13-17

Identification of prior art discussed: Yonemitsu et al stated the conventional HIV-1 liposome has low efficiency in gene delivery.

Description of the general nature of what was agreed to if an agreement was reached, or any other comments: Applicant's rep. indicated the cited Yonemitsu reference stated the low efficiency of HIV-1 liposome used by applicants and the unpredictability of gene therapy would not predictably reach the instantly claimed invention. The examiners indicated the art of record also show that local delivery of therapeutic gene to brain would function to certain degree. The HGF & VEGF affects vascular endothelial cells. But would consider the evidence stated by Yonemitsu et al.

☐ 1. It is not necessary for applicant to provide a separate record of the substance of the interview.

Unless the paragraph below has been checked to indicate to the contrary, A FORMAL WRITTEN RESPONSE TO THE LAST OFFICE ACTION IS NOT WAIVED AND MUST INCLUDE THE SUBSTANCE OF THE INTERVIEW (e.g., items 1-7 on the reverse side of this form). If a response to the last Office action has already been filed, then applicant is given one month from this interview date to provide a statement of the substance of the interview.

☐ 2. Since the examiner's interview summary above (including any attachments) reflects a complete response to each of the objections, rejections and requirements that may be present in the last Office action, and since the claims are now allowable, this completed form is considered to fulfill the response requirements of the last Office action. Applicant is not relieved from providing a separate record of the substance of the interview unless box 1 above is also checked.

Examiner's Signature